Aarti Pharmalabs Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 5/6
Aarti Pharmalabs has a total shareholder equity of ₹18.6B and total debt of ₹3.7B, which brings its debt-to-equity ratio to 19.8%. Its total assets and total liabilities are ₹27.8B and ₹9.2B respectively. Aarti Pharmalabs's EBIT is ₹3.2B making its interest coverage ratio 19.8. It has cash and short-term investments of ₹995.1M.
Wichtige Informationen
19.8%
Verhältnis von Schulden zu Eigenkapital
₹3.68b
Verschuldung
| Zinsdeckungsgrad | 19.8x |
| Bargeld | ₹995.13m |
| Eigenkapital | ₹18.57b |
| Gesamtverbindlichkeiten | ₹9.20b |
| Gesamtvermögen | ₹27.77b |
Jüngste Berichte zur Finanzlage
These 4 Measures Indicate That Aarti Pharmalabs (NSE:AARTIPHARM) Is Using Debt Reasonably Well
Mar 21
Recent updates
Does Aarti Pharmalabs (NSE:AARTIPHARM) Deserve A Spot On Your Watchlist?
Oct 23Should You Be Adding Aarti Pharmalabs (NSE:AARTIPHARM) To Your Watchlist Today?
May 31Estimating The Intrinsic Value Of Aarti Pharmalabs Limited (NSE:AARTIPHARM)
Apr 19These 4 Measures Indicate That Aarti Pharmalabs (NSE:AARTIPHARM) Is Using Debt Reasonably Well
Mar 21Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: AARTIPHARM's short term assets (₹13.8B) exceed its short term liabilities (₹6.8B).
Langfristige Verbindlichkeiten: AARTIPHARM's short term assets (₹13.8B) exceed its long term liabilities (₹2.4B).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: AARTIPHARM's net debt to equity ratio (14.4%) is considered satisfactory.
Schulden abbauen: Insufficient data to determine if AARTIPHARM's debt to equity ratio has reduced over the past 5 years.
Schuldendeckung: AARTIPHARM's debt is well covered by operating cash flow (57.5%).
Zinsdeckung: AARTIPHARM's interest payments on its debt are well covered by EBIT (19.8x coverage).